Exicure was an expiring company with no money or active pipeline. | A couple of months ago, Exicure was an expiring company ...

As multisite clinical research corporations (MCRCs) proliferate to meet the increased demand for larger clinical trials that ...

Biogen has been in the news recently after longtime partner Sage Therapeutics filed a lawsuit against the company after ...

Robert F. Kennedy Jr. will be pulling his investments from two biotechs if he is confirmed to lead the U.S. Department of ...

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...

Beta Bionics has set the terms for its plan to go public, with a goal of raising at least $114 million to support its ...

A year after going public, ArriVent BioPharma is continuing to bolster its antibody-drug conjugate pipeline via licensing ...

Following last year’s launches of several all-in-one CRO offerings, Lindus Health is starting 2025 strong by closing a $55 ...

Tris Pharma has pointed to a phase 3 win for its pain relief drug as demonstrating the candidate’s potential to help resolve the opioid crisis. | Tris Pharma has pointed to a phase 3 win for its pain ...

Among his first actions as president, Donald Trump has rescinded an executive order signed during the Biden administration ...

Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an ...